Exploring the Physiological Mechanisms of Austism Through Organoids

Exploring the Physiologicla Mechainisms of Austism Through Organoids Derived Differentiated Cells of Individuals With Autism

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07494331

Acronym

EXPECT HYPE

Enrollment

Registered

2026-03-27

Start date

2026-05-01

Completion date

2028-05-01

Last updated

2026-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism Spectrum Disorder (ASD

Keywords

ASD, organoid

Brief summary

Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder affecting approximately 1% of the population, characterized by difficulties with social interaction and communication. Studies have identified more than 200 genes linked to ASD, particularly those involved in chromatin remodeling and synaptic neuronal connectivity (CHD8, SCN2A, NLGN3-4X, SHANK1-3). The goal of the project is to decipher the biological mechanisms underlying ASD in order to develop therapeutic strategies, using innovative preclinical models such as organoids.

Detailed description

Each participant's involvement in this study is limited to one visit. This study requires only a blood draw (5 to 30 minutes), which will be performed at the CIC at Robert-Debré, and the completion of questionnaires for parents (SRS) and unaffected siblings (SRS, ADHD-RS, SDQ). Additional tests or questionnaires may be offered at a later stage if clinically necessary.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

2 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* A child diagnosed with an autism spectrum disorder in accordance with clinical practice guidelines * A sibling without an autism spectrum disorder (SRS \< 65) * Biological parents * Children and parents must be enrolled in a social security program, Universal Health Coverage (CMU), or an equivalent program.

Exclusion criteria

* Refusal to undergo a blood test * Uncontrolled (unstabilized) medical condition (including psychiatric conditions) that precludes participation in the study * Sibling with an SRS score \> 65 at screening or under 2 years old

Design outcomes

Primary

Measure	Time frame	Description
Production of organoïds	2 years	To study the cellular mechanisms affected by the presence of the abnormalities identified in the participant with ASD

Countries

France

Contacts

CONTACTRichard DELORME, Prof

richard.delorme@aphp.fr0033(0)140034130

Outcome results